The 15th Annual BIO Investor Forum wrapped up in San Francisco yesterday, having exceeded all prior years’ numbers of meetings arranged through the BIO One-on-One Partnering™ system. Both the conference and the partnering system are designed to help investors identify the latest trends and provide biotech innovators an opportunity to secure the funding necessary to bring their technologies to market.
This year’s forum brought together over 880 attendees including 240 investors and 155 presenting companies. There were 2,176 meetings scheduled through BIO One-on-One Partnering™ – a 20% increase over last year’s event.
Joanne Duncan, BIO’s President of Membership and Business Operations had this to say about #BIF16:
“So much has changed since our first BIO Investor Conference in 2001. Back then we were still figuring out how many genes were in the human genome and only about half the companies founded that year are still with us. Yet the enthusiasm and drive to develop life-saving therapies and cures lives on in the form of new partnerships and emerging companies. This year we had a phenomenal event with a record-breaking number of partnering meetings, 155 company presentations and multiple sessions addressing industry trends. Bringing ideas from lab to market can only happen when investors see value in innovative technology.”
Topics covered during the conference were many and included the innovation expected from CRISPR technology, the impact of the presidential campaign on the biotech sector, immune-oncology, approval of gene therapy treatments and the flow of capital in the public and private marketplace.
Early next year BIO will hold the CEO & Investor Conference which is focused on established and emerging publicly traded and select private biotech companies. One of the largest investor conferences, the event will be held February 13-14 at the Waldorf Astoria in New York
Media registration is now open and complimentary to qualified reporters working full time for print, broadcast or a web publication with valid press credentials.